Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Cancer Cell International
Published in: Cancer Cell International 1/2023

Open Access 01-12-2023 | Research

MFI2 upregulation promotes malignant progression through EGF/FAK signaling in oral cavity squamous cell carcinoma

Authors: Wei-Chen Yen, Kai-Ping Chang, Cheng-Yi Chen, Yenlin Huang, Ting-Wen Chen, Hsing-Wen Cheng, Jui-Shan Yi, Chun-Chia Cheng, Chih-Ching Wu, Chun-I Wang

Published in: Cancer Cell International | Issue 1/2023

Login to get access

Abstract

Oral squamous cell carcinoma (OSCC) is the predominant histological type of the head and neck squamous cell carcinoma (HNSCC). By comparing the differentially expressed genes (DEGs) in OSCC-TCGA patients with copy number variations (CNVs) that we identify in OSCC-OncoScan dataset, we herein identified 37 dysregulated candidate genes. Among these potential candidate genes, 26 have been previously reported as dysregulated proteins or genes in HNSCC. Among 11 novel candidates, the overall survival analysis revealed that melanotransferrin (MFI2) is the most significant prognostic molecular in OSCC-TCGA patients. Another independent Taiwanese cohort confirmed that higher MFI2 transcript levels were significantly associated with poor prognosis. Mechanistically, we found that knockdown of MFI2 reduced cell viability, migration and invasion via modulating EGF/FAK signaling in OSCC cells. Collectively, our results support a mechanistic understanding of a novel role for MFI2 in promoting cell invasiveness in OSCC.
Appendix
Available only for authorised users
Literature
1.
2.
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209–49.PubMedCrossRef
3.
Wang CI, Yu CJ, Huang Y, Yi JS, Cheng HW, Kao HK, et al. Association of overexpressed karyopherin alpha 2 with poor survival and its contribution to interleukin-1beta-induced matrix metalloproteinase expression in oral cancer. Head Neck. 2018;40:1719–33.PubMed
4.
5.
Wang TH, Hsia SM, Shih YH, Shieh TM. Association of smoking, alcohol use, and betel quid chewing with epigenetic aberrations in cancers. Int J Mol Sci. 2017;18:1210.PubMedPubMedCentralCrossRef
6.
Lee YA, Li S, Chen Y, Li Q, Chen CJ, Hsu WL, et al. Tobacco smoking, alcohol drinking, betel quid chewing, and the risk of head and neck cancer in an East Asian population. Head Neck. 2019;41:92–102.PubMed
7.
Wang CI, Kao HK, Chen TW, Huang Y, Cheng HW, Yi JS, et al. Characterization of copy number variations in oral cavity squamous cell carcinoma reveals a novel role for MLLT3 in cell invasiveness. Oncologist. 2019;24:e1388–400.PubMedPubMedCentralCrossRef
8.
Paluncic J, Kovacevic Z, Jansson PJ, Kalinowski D, Merlot AM, Huang ML, et al. Roads to melanoma: key pathways and emerging players in melanoma progression and oncogenic signaling. Biochim Biophys Acta. 2016;1863:770–84.PubMedCrossRef
9.
Brown JP, Nishiyama K, Hellstrom I, Hellstrom KE. Structural characterization of human melanoma-associated antigen p97 with monoclonal antibodies. J Immunol. 1981;127:539–46.PubMedCrossRef
10.
Richardson DR. The role of the membrane-bound tumour antigen, melanotransferrin (p97), in iron uptake by the human malignant melanoma cell. Eur J Biochem. 2000;267:1290–8.PubMedCrossRef
11.
Food MR, Sekyere EO, Richardson DR. The soluble form of the membrane-bound transferrin homologue, melanotransferrin, inefficiently donates iron to cells via nonspecific internalization and degradation of the protein. Eur J Biochem. 2002;269:4435–45.PubMedCrossRef
12.
13.
Suryo Rahmanto Y, Dunn LL, Richardson DR. Identification of distinct changes in gene expression after modulation of melanoma tumor antigen p97 (melanotransferrin) in multiple models in vitro and in vivo. Carcinogenesis. 2007;28:2172–83.PubMedCrossRef
14.
Laube F, Glanz D. Modulation of melanotransferrin and Transferrin Receptor 1 (TFRC)- and CD44-based Signaling for TFRC Up-regulation in Human Melanoma Cells. Anticancer Res. 2017;37:3001–7.PubMed
15.
Demeule M, Bertrand Y, Michaud-Levesque J, Jodoin J, Rolland Y, Gabathuler R, et al. Regulation of plasminogen activation: a role for melanotransferrin (p97) in cell migration. Blood. 2003;102:1723–31.PubMedCrossRef
16.
Michaud-Levesque J, Demeule M, Beliveau R. In vivo inhibition of angiogenesis by a soluble form of melanotransferrin. Carcinogenesis. 2007;28:280–8.PubMedCrossRef
17.
Dubon M, Lee S, Park JH, Lee JY, Kang D. The role of melanotransferrin (CD228) in the regulation of the differentiation of human bone marrow-derived mesenchymal stem cells (hBM-MSC). Int J Med Sci. 2021;18:1580–91.PubMedPubMedCentralCrossRef
18.
Singh CSB, Eyford BA, Abraham T, Munro L, Choi KB, Okon M, et al. Discovery of a highly conserved peptide in the iron transporter melanotransferrin that traverses an intact blood brain barrier and localizes in neural cells. Front Neurosci. 2021;15:596976.PubMedPubMedCentralCrossRef
19.
Shin J, Kim HJ, Kim G, Song M, Woo SJ, Lee ST, et al. Discovery of melanotransferrin as a serological marker of colorectal cancer by secretome analysis and quantitative proteomics. J Proteome Res. 2014;13:4919–31.PubMedCrossRef
20.
Dus-Szachniewicz K, Ostasiewicz P, Wozniak M, Kolodziej P, Wisniewski JR, Ziolkowski P. Pattern of melanotransferrin expression in human colorectal tissues: an immunohistochemical study on potential clinical application. Anticancer Res. 2015;35:6551–61.PubMed
21.
Sawaki K, Kanda M, Umeda S, Miwa T, Tanaka C, Kobayashi D, et al. Level of melanotransferrin in tissue and sera serves as a prognostic marker of gastric cancer. Anticancer Res. 2019;39:6125–33.PubMedCrossRef
22.
Lei Y, Lu Z, Huang J, Zang R, Che Y, Mao S, et al. The membrane-bound and soluble form of melanotransferrin function independently in the diagnosis and targeted therapy of lung cancer. Cell Death Dis. 2020;11:933.PubMedPubMedCentralCrossRef
23.
Li B, Dewey CN. RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome. BMC Bioinform. 2011;12:323.CrossRef
24.
Witsch E, Sela M, Yarden Y. Roles for growth factors in cancer progression. Physiology (Bethesda). 2010;25:85–101.PubMed
25.
Bhatia A. Targeting epidermal growth factor receptor in head and neck cancer. Cancer J. 2022;28:331–8.PubMedCrossRef
26.
Chang KP, Chang YT, Liao CT, Yen TC, Chen IH, Chang YL, et al. Prognostic cytokine markers in peripheral blood for oral cavity squamous cell carcinoma identified by multiplexed immunobead-based profiling. Clin Chim Acta. 2011;412:980–7.PubMedCrossRef
27.
An SJ, Anneken A, Xi Z, Choi C, Schlessinger J, Toomre D. Regulation of EGF-stimulated activation of the PI-3K/AKT pathway by exocyst-mediated exocytosis. Proc Natl Acad Sci USA. 2022;119:e2208947119.PubMedPubMedCentralCrossRef
28.
Huang K, Gao N, Bian D, Zhai Q, Yang P, Li M, et al. Correlation between FAK and EGF-induced EMT in colorectal cancer cells. J Oncol. 2020;2020:5428920.PubMedPubMedCentralCrossRef
29.
Kraus S, Benard O, Naor Z, Seger R. C-Src is activated by the EGF receptor in a pathway that mediates JNK and ERK activation by gonadotropin-releasing hormone in COS7 cells. Int J Mol Sci. 2020;21:8575.PubMedPubMedCentralCrossRef
30.
31.
Shao X, Lv N, Liao J, Long J, Xue R, Ai N, et al. Copy number variation is highly correlated with differential gene expression: a pan-cancer study. BMC Med Genet. 2019;20:175.PubMedPubMedCentralCrossRef
32.
Sekyere E, Food MR, Richardson DR. A second melanotransferrin gene (MTf2) and a novel protein isoform: explanation for the membrane-bound and soluble forms of melanotransferrin? FEBS Lett. 2002;512:350–2.PubMedCrossRef
33.
34.
Bill A, Gutierrez A, Kulkarni S, Kemp C, Bonenfant D, Voshol H, et al. ANO1/TMEM16A interacts with EGFR and correlates with sensitivity to EGFR-targeting therapy in head and neck cancer. Oncotarget. 2015;6:9173–88.PubMedPubMedCentralCrossRef
35.
Crottes D, Lin YT, Peters CJ, Gilchrist JM, Wiita AP, Jan YN, et al. TMEM16A controls EGF-induced calcium signaling implicated in pancreatic cancer prognosis. Proc Natl Acad Sci USA. 2019;116:13026–35.PubMedPubMedCentralCrossRef
36.
Sieg DJ, Hauck CR, Ilic D, Klingbeil CK, Schaefer E, Damsky CH, et al. FAK integrates growth-factor and integrin signals to promote cell migration. Nat Cell Biol. 2000;2:249–56.PubMedCrossRef
37.
Le Coq J, Acebron I, Rodrigo Martin B, Lopez Navajas P, Lietha D. New insights into FAK structure and function in focal adhesions. J Cell Sci. 2022;135:jcs259089.PubMedCrossRef
38.
Zhang Y, Sun X. Role of focal adhesion kinase in head and neck squamous cell carcinoma and its therapeutic prospect. Onco Targets Ther. 2020;13:10207–20.PubMedPubMedCentralCrossRef
39.
Yang L, Qiao P, Zhang J, Huang S, Hu A. Rho-associated kinase1 promotes laryngeal squamous cell carcinoma tumorigenesis and progression via the FAK signaling pathway. Discov Oncol. 2022;13:100.PubMedPubMedCentralCrossRef
40.
Chiu YW, Liou LY, Chen PT, Huang CM, Luo FJ, Hsu YK, et al. Tyrosine 397 phosphorylation is critical for FAK-promoted Rac1 activation and invasive properties in oral squamous cell carcinoma cells. Lab Invest. 2016;96:296–306.PubMedCrossRef
41.
Kato A, Kato K, Miyazawa H, Kobayashi H, Noguchi N, Kawashiri S. Focal adhesion kinase (FAK) overexpression and phosphorylation in oral squamous cell carcinoma and their clinicopathological significance. Pathol Oncol Res. 2020;26:1659–67.PubMedCrossRef
42.
Skinner HD, Giri U, Yang L, Woo SH, Story MD, Pickering CR, et al. Proteomic profiling identifies PTK2/FAK as a driver of radioresistance in HPV-negative head and neck cancer. Clin Cancer Res. 2016;22:4643–50.PubMedPubMedCentralCrossRef
43.
Huang WC, Jang TH, Tung SL, Yen TC, Chan SH, Wang LH. A novel miR-365-3p/EHF/keratin 16 axis promotes oral squamous cell carcinoma metastasis, cancer stemness and drug resistance via enhancing beta5-integrin/c-met signaling pathway. J Exp Clin Cancer Res. 2019;38:89.PubMedPubMedCentralCrossRef
44.
Zhou Y, Zhang L, Pan H, Wang B, Yan F, Fang X, et al. Bmi1 essentially mediates podocalyxin-enhanced Cisplatin chemoresistance in oral tongue squamous cell carcinoma. PLoS ONE. 2015;10:e0123208.PubMedPubMedCentralCrossRef
45.
Toomes C, Jackson A, Maguire K, Wood J, Gollin S, Ishwad C, Paterson I, Prime S, Parkinson K, Bell S, Woods G, Markham A, Oliver R, Woodward R, Sloan P, Dixon M, Read A, Thakker N. The presence of multiple regions of homozygous deletion at the CSMD1 locus in oral squamous cell carcinoma question the role of CSMD1 in head and neck carcinogenesis. Genes Chromosom Cancer. 2003;37:132–40.PubMedCrossRef
46.
Joo YH, Park SW, Jung SH, Lee YS, Nam IC, Cho KJ, Park JO, Chung YJ, Kim MS. Recurrent loss of the FHIT gene and its impact on lymphatic metastasis in early oral squamous cell carcinoma. Acta Otolaryngol. 2013;133:992–9.PubMedCrossRef
47.
Liu CJ, Lin SC, Chen YJ, Chang KM, Chang KW. Array-comparative genomic hybridization to detect genomewide changes in microdissected primary and metastatic oral squamous cell carcinomas. Mol Carcinog. 2006;45:721–31.PubMedCrossRef
48.
Alaeddini M, Etemad-Moghadam S. Immunohistochemical profile of oral mucosal and head and neck cutaneous melanoma. J Oral Pathol Med. 2015;44:234–8.PubMedCrossRef
49.
Chen C, Ricks S, Doody DR, Fitzgibbons ED, Porter PL, Schwartz SM. N-Acetyltransferase 2 polymorphisms, cigarette smoking and alcohol consumption, and oral squamous cell cancer risk. Carcinogenesis. 2001;22:1993–9.PubMedCrossRef
50.
Ghosh S, Ghosh A, Maiti GP, Alam N, Roy A, Roychoudhury S, Panda CK. Alterations of ROBO1/DUTT1 and ROBO2 loci in early dysplastic lesions of head and neck: clinical and prognostic implications. Hum Genet. 2009;125:189–98.PubMedCrossRef
51.
Rowley H, Jones A, Spandidos D, Field J. Definition of a tumor suppressor gene locus on the short arm of chromosome 3 in squamous cell carcinoma of the head and neck by means of microsatellite markers. Arch Otolaryngol Head Neck Surg. 1996;122:497–501.PubMedCrossRef
52.
Oliveira Alves MG, Carta CF, Padin-Iruegas ME, Perez-Sayans M, Suarez-Penaranda JM, Issa JS, Garcia-Garcia A, Almeida JD. Expression of ATP6V1C1 during oral carcinogenesis. Biotech Histochem. 2016;91:263–8.PubMedCrossRef
53.
Al-Hebshi NN, Li S, Nasher AT, El-Setouhy M, Alsanosi R, Blancato J, Loffredo C. Exome sequencing of oral squamous cell carcinoma in users of Arabian snuff reveals novel candidates for driver genes. Int J Cancer. 2016;139:363–72.PubMedPubMedCentralCrossRef
54.
Wu ZH, Yun T, Cheng Q. Data mining identifies six proteins that can act as prognostic markers for head and neck squamous cell carcinoma. Cell Transplant. 2020;29:963689720929308.PubMedCrossRef
55.
Fang L, Gao L, Xie L, Xiao G. GC7 enhances cisplatin sensitivity via STAT3 signaling pathway inhibition and eIF5A2 inactivation in mesenchymal phenotype oral cancer cells. Oncol Rep. 2018;39:1283–91.PubMed
56.
Chen YJ, Lin SC, Kao T, Chang CS, Hong PS, Shieh TM, Chang KW. Genome-wide profiling of oral squamous cell carcinoma. J Pathol. 2004;204:326–32.PubMedCrossRef
57.
Ghosh A, Maiti GP, Bandopadhyay MN, Chakraborty J, Biswas J, Roychoudhury S, Panda CK. Inactivation of 9q22.3 tumor suppressor genes predict outcome for patients with head and neck squamous cell carcinoma. Anticancer Res. 2013;33:1215–20.PubMed
58.
Turke C, Horn S, Petto C, Labudde D, Lauer G, Wittenburg G. Loss of heterozygosity in FANCG, FANCF and BRIP1 from head and neck squamous cell carcinoma of the oral cavity. Int J Oncol. 2017;50:2207–20.PubMedCrossRef
59.
Koukourakis MI, Giatromanolaki A, Sivridis E, Simopoulos C, Turley H, Talks K, Gatter KC, Harris AL. Hypoxia-inducible factor (HIF1A and HIF2A), angiogenesis, and chemoradiotherapy outcome of squamous cell head-and-neck cancer. Int J Radiat Oncol Biol Phys. 2002;53:1192–202.PubMedCrossRef
60.
Feng X, Lin J, Xing S, Liu W, Zhang G. Higher IGFBP-1 to IGF-1 serum ratio predicts unfavourable survival in patients with nasopharyngeal carcinoma. BMC Cancer. 2017;17:90.PubMedPubMedCentralCrossRef
61.
Sakata J, Hirosue A, Yoshida R, Matsuoka Y, Kawahara K, Arita H, Nakashima H, Yamamoto T, Nagata M, Kawaguchi S, Gohara S, Nagao Y, Yamana K, Toya R, Murakami R, Kuwahara Y, Fukumoto M, Nakayama H. Enhanced expression of IGFBP-3 reduces radiosensitivity and is associated with poor prognosis in oral squamous cell carcinoma. Cancers (Basel). 2020;12:494.PubMedCrossRef
62.
Chen YJ, Liao YJ, Lin F, Sun SG, Zhao XL, Qin JH, Rao SQ. Shared functional modules for nasopharyngeal and oral squamous cell carcinoma identified by network analysis of transcriptomes. Yi Chuan. 2019;41:146–57.PubMed
63.
Kurimoto K, Hayashi M, Guerrero-Preston R, Koike M, Kanda M, Hirabayashi S, Tanabe H, Takano N, Iwata N, Niwa Y, Takami H, Kobayashi D, Tanaka C, Yamada S, Nakayama G, Sugimoto H, Fujii T, Fujiwara M, Kodera Y. PAX5 gene as a novel methylation marker that predicts both clinical outcome and cisplatin sensitivity in esophageal squamous cell carcinoma. Epigenetics. 2017;12:865–74.PubMedPubMedCentralCrossRef
64.
Zhao H, Chen M, Wang J, Cao G, Chen W, Xu J. PCNA-associated factor KIAA0101 transcriptionally induced by ELK1 controls cell proliferation and apoptosis in nasopharyngeal carcinoma: an integrated bioinformatics and experimental study. Aging (Albany NY). 2020;12:5992–6017.PubMedCrossRef
65.
Pawar H, Kashyap MK, Sahasrabuddhe NA, Renuse S, Harsha HC, Kumar P, Sharma J, Kandasamy K, Marimuthu A, Nair B, Rajagopalan S, Maharudraiah J, Premalatha CS, Kumar KV, Vijayakumar M, Chaerkady R, Prasad TS, Kumar RV, Pandey A. Quantitative tissue proteomics of esophageal squamous cell carcinoma for novel biomarker discovery. Cancer Biol Ther. 2011;12:510–22.PubMedPubMedCentralCrossRef
66.
Dodd LE, Sengupta S, Chen IH, den Boon JA, Cheng YJ, Westra W, Newton MA, Mittl BF, McShane L, Chen CJ, Ahlquist P, Hildesheim A. Genes involved in DNA repair and nitrosamine metabolism and those located on chromosome 14q32 are dysregulated in nasopharyngeal carcinoma. Cancer Epidemiol Biomarkers Prev. 2006;15:2216–25.PubMedCrossRef
67.
Yong ZW, Zaini ZM, Kallarakkal TG, Karen-Ng LP, Rahman ZA, Ismail SM, Sharifah NA, Mustafa WM, Abraham MT, Tay KK, Zain RB. Genetic alterations of chromosome 8 genes in oral cancer. Sci Rep. 2014;4:6073.PubMedPubMedCentralCrossRef
68.
Sakamoto T, Kawano S, Matsubara R, Goto Y, Jinno T, Maruse Y, Kaneko N, Hashiguchi Y, Hattori T, Tanaka S, Kitamura R, Kiyoshima T, Nakamura S. Critical roles of Wnt5a-Ror2 signaling in aggressiveness of tongue squamous cell carcinoma and production of matrix metalloproteinase-2 via DeltaNp63beta-mediated epithelial-mesenchymal transition. Oral Oncol. 2017;69:15–25.PubMedCrossRef
69.
Wada S, Noguchi T, Takeno S, Kawahara K. PIK3CA and TFRC located in 3q are new prognostic factors in esophageal squamous cell carcinoma. Ann Surg Oncol. 2006;13:961–6.PubMedCrossRef
70.
King KE, George AL, Sakakibara N, Mahmood K, Moses MA, Weinberg WC. Intersection of the p63 and NF-kappaB pathways in epithelial homeostasis and disease. Mol Carcinog. 2019;58:1571–80.PubMedCrossRef
Metadata
Title
MFI2 upregulation promotes malignant progression through EGF/FAK signaling in oral cavity squamous cell carcinoma
Authors
Wei-Chen Yen
Kai-Ping Chang
Cheng-Yi Chen
Yenlin Huang
Ting-Wen Chen
Hsing-Wen Cheng
Jui-Shan Yi
Chun-Chia Cheng
Chih-Ching Wu
Chun-I Wang
Publication date
01-12-2023
Publisher
BioMed Central
Published in
Cancer Cell International / Issue 1/2023
Electronic ISSN: 1475-2867
DOI
https://doi.org/10.1186/s12935-023-02956-0

Other articles of this Issue 1/2023

Cancer Cell International 1/2023 Go to the issue

Research

ATG4B and pS383/392-ATG4B serve as potential biomarkers and therapeutic targets of colorectal cancer

Research

DHRS4-AS1 regulate gastric cancer apoptosis and cell proliferation by destabilizing DHX9 and inhibited the association between DHX9 and ILF3

Research

Environmental signals perceived by the brain abate pro-metastatic monocytes by dampening glucocorticoids receptor signaling

Research

The novel oncogenic factor TET3 combines with AHR to promote thyroid cancer lymphangiogenesis via the HIF-1α/VEGF signaling pathway

Correction

Correction: Camels’ biological fluids contained nanobodies: promising avenue in cancer therapy

Correction

Correction: Current view of liver cancer cell-of-origin and proposed mechanisms precluding its proper determination
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits